Patrick C Walsh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10741758/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Development of Human Benign Prostatic Hyperplasia with Age. Journal of Urology, 1984, 132, 474-479.	0.4	2,145
2	Impotence Following Radical Prostatectomy: Insight Into Etiology and Prevention. Journal of Urology, 1982, 128, 492-497.	0.4	1,451
3	Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2005, 294, 433.	7.4	1,186
4	The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer. Journal of Urology, 1993, 150, 110-114.	0.4	1,152
5	The Effect of Finasteride in Men with Benign Prostatic Hyperplasia. New England Journal of Medicine, 1992, 327, 1185-1191.	27.0	1,068
6	Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease. JAMA - Journal of the American Medical Association, 1998, 279, 1542.	7.4	990
7	Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate, 1983, 4, 473-485.	2.3	974
8	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001, 58, 843-848.	1.0	943
9	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 555-565.	1.8	939
10	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics, 2007, 39, 631-637.	21.4	818
11	Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 1993, 71, 3582-3593.	4.1	709
12	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Journal of Urology, 2003, 169, 517-523.	0.4	691
13	Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 162-200.	4.9	671
14	Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years. Journal of Urology, 1994, 152, 1831-1836.	0.4	650
15	Family history and the risk of prostate cancer. Prostate, 1990, 17, 337-347.	2.3	609
16	Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2008, 299, 2760.	7.4	586
17	Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical Prostatectomy. Journal of Urology, 1988, 139, 766-772.	0.4	580
18	Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology, 2000, 55, 58-61.	1.0	578

#	Article	IF	CITATIONS
19	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.4	574
20	Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia. Journal of Urology, 1990, 143, 747-752.	0.4	568
21	Familial Incomplete Male Pseudohermaphroditism, Type 2. New England Journal of Medicine, 1974, 291, 944-949.	27.0	567
22	Germline Mutations in <i>HOXB13</i> and Prostate-Cancer Risk. New England Journal of Medicine, 2012, 366, 141-149.	27.0	566
23	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. Journal of Clinical Oncology, 2011, 29, 2185-2190.	1.6	545
24	PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 1997, 24, 395-406.	1.8	542
25	Prognostic <scp>G</scp> leason grade grouping: data based on the modified <scp>G</scp> leason scoring system. BJU International, 2013, 111, 753-760.	2.5	540
26	Prediction of Progression Following Radical Prostatectomy. American Journal of Surgical Pathology, 1996, 20, 286-292.	3.7	532
27	Hereditary Prostate Cancer: Epidemiologic and Clinical Features. Journal of Urology, 1993, 150, 797-802.	0.4	519
28	Sexual Function following Radical Prostatectomy: Influence of Preservation of Neurovascular Bundles. Journal of Urology, 1991, 145, 998-1002.	0.4	505
29	Comparison of Magnetic Resonance Imaging and Ultrasonography in Staging Early Prostate Cancer. New England Journal of Medicine, 1990, 323, 621-626.	27.0	498
30	Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer. Cancer Research, 2004, 64, 1975-1986.	0.9	467
31	SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY. Urologic Clinics of North America, 1993, 20, 713-725.	1.8	451
32	Impact of Anatomical Radical Prostatectomy on Urinary Continence. Journal of Urology, 1991, 145, 512-514.	0.4	440
33	Precise Localization of the Autonomic Nerves From the pelvic Plexus to the Corpora Cavernosa: a Detailed Anatomical Study of the Adult Male Pelvis. Journal of Urology, 1985, 133, 207-212.	0.4	430
34	Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005. Urology, 2007, 69, 1095-1101.	1.0	410
35	Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 1994, 43, 649-659.	1.0	376
36	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genetics, 2008, 40, 281-283.	21.4	357

#	Article	IF	CITATIONS
37	Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. Journal of Urology, 2017, 197, S165-S170.	0.4	356
38	Influence of Capsular Penetration on Progression Following Radical Prostatectomy: A Study of 196 Cases with Long-Term Followup. Journal of Urology, 1993, 150, 135-141.	0.4	353
39	The Effect of Nafarelin Acetate, a Luteinizing-Hormone–Releasing Hormone Agonist, on Benign Prostatic Hyperplasia. New England Journal of Medicine, 1987, 317, 599-604.	27.0	343
40	Radical Surgery for Prostatic Cancer. Cancer, 1980, 45, 1906-1911.	4.1	323
41	An updated prostate cancer staging nomogram (<scp>P</scp> artin tables) based on cases from 2006 to 2011. BJU International, 2013, 111, 22-29.	2.5	323
42	Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nature Genetics, 2002, 32, 321-325.	21.4	318
43	Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup. Journal of Urology, 1993, 149, 1478-1481.	0.4	314
44	ANATOMICAL EXTENT OF LYMPH NODE DISSECTION: IMPACT ON MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 172, 1840-1844.	0.4	313
45	Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience. Journal of Urology, 2007, 178, 2359-2365.	0.4	308
46	Pathological Factors that Influence Prognosis in Stage a Prostatic Cancer: the Influence of Extent Versus Grade. Journal of Urology, 1981, 125, 516-520.	0.4	307
47	An Anatomical Approach to the Surgical Management of the Dorsal Vein and Santorini's Plexus During Radical Retropubic Surgery. Journal of Urology, 1979, 121, 198-200.	0.4	303
48	Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology, 2000, 56, 823-827.	1.0	298
49	Prognosis of Untreated Stage A1 Prostatic Carcinoma: A Study of 94 Cases with Extended Followup. Journal of Urology, 1986, 136, 837-839.	0.4	286
50	Neuroanatomical Approach to Radical Cystoprostatectomy with Preservation of Sexual Function. Journal of Urology, 1987, 138, 1402-1406.	0.4	276
51	Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 2000, 56, 255-260.	1.0	275
52	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Journal of Urology, 2003, 169, 517-23.	0.4	271
53	NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS. Journal of Urology, 1998, 160, 2407-2411.	0.4	266
54	ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2001, 166, 416-419.	0.4	266

#	Article	IF	CITATIONS
55	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	1.9	256
56	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. Journal of Clinical Oncology, 2010, 28, 2810-2816.	1.6	237
57	Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP. Journal of the National Cancer Institute, 2007, 99, 1836-1844.	6.3	235
58	Serum LH and FSH During Sexual Maturation in the Male Rat: Effect of Castration and Cryptorchidism. Endocrinology, 1971, 88, 120-128.	2.8	233
59	Immunohistochemical Localization of Nitric Oxide Synthase in the Autonomic Innervation of the Human Penis. Journal of Urology, 1993, 150, 73-76.	0.4	233
60	RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER PROVIDES DURABLE CANCER CONTROL WITH EXCELLENT QUALITY OF LIFE: A STRUCTURED DEBATE. Journal of Urology, 2000, 163, 1802-1807.	0.4	232
61	Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer, 1991, 67, 3057-3064.	4.1	221
62	The natural history of metastatic progression in men with prostateâ€specific antigen recurrence after radical prostatectomy: longâ€ŧerm followâ€up. BJU International, 2012, 109, 32-39.	2.5	221
63	EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT: PRELIMINARY RESULTS. Journal of Urology, 2002, 167, 1231-1234.	0.4	203
64	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.9	202
65	LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 159, 173-178.	0.4	200
66	Radical Prostatectomy with Preservation of Sexual Function: Pathological Findings in the First 100 Cases. Journal of Urology, 1985, 134, 1146-1148.	0.4	193
67	Potency Following Radical Prostatectomy with Wide Unilateral Excision of the Neurovascular Bundle. Journal of Urology, 1987, 138, 823-827.	0.4	189
68	Radical Perineal Prostatectomy for Clinical Stage B2 Carcinoma of the Prostate. Journal of Urology, 1982, 127, 704-706.	0.4	187
69	Clinical and Experimental Studies of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 1990, 17, 461-475.	1.8	186
70	The Rat as a Model for the Study of Penile Erection. Journal of Urology, 1989, 141, 656-661.	0.4	184
71	Influence of Age and Endocrine Factors on the Volume of Benign Prostatic Hyperplasia. Journal of Urology, 1991, 145, 405-409.	0.4	183
72	Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 1995, 45, 831-838.	1.0	179

#	Article	IF	CITATIONS
73	Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. Journal of Clinical Oncology, 2007, 25, 1765-1771.	1.6	177
74	Localized Prostate Cancer. New England Journal of Medicine, 2007, 357, 2696-2705.	27.0	176
75	Correlation of Clinical Stage, Serum Prostatic Acid Phosphatase and Preoperative Gleason Grade with Final Pathological Stage in 275 Patients with Clinically Localized Adenocarcinoma of the Prostate. Journal of Urology, 1987, 138, 92-98.	0.4	175
76	Clinical and Cost Impact of Second-opinion Pathology. American Journal of Surgical Pathology, 1996, 20, 851-857.	3.7	174
77	Correlation of Prostatic Nuclear Androgen Receptor Content with Duration of Response and Survival Following Hormonal Therapy in Advanced Prostatic Cancer. Journal of Urology, 1982, 127, 466-471.	0.4	173
78	USE OF REPEAT SEXTANT AND TRANSITION ZONE BIOPSIES FOR ASSESSING EXTENT OF PROSTATE CANCER. Journal of Urology, 1997, 158, 1886-1890.	0.4	173
79	Morphometric Measurement of Tumor Volume and Per Cent of Gland Involvement as Predictors of Pathological Stage in Clinical Stage B Prostate Cancer. Journal of Urology, 1989, 141, 341-345.	0.4	168
80	Hormonal Regulation of Testicular Descent: Experimental and Clinical Observations. Journal of Urology, 1977, 118, 985-990.	0.4	167
81	Prospective Evaluation of Men With Stage T1C Adenocarcinoma of the Prostate. Journal of Urology, 1997, 157, 2206-2209.	0.4	167
82	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 2013, 132, 5-14.	3.8	166
83	Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 1993, 17, 336-341.	3.7	164
84	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. Journal of Clinical Oncology, 2012, 30, 4294-4296.	1.6	162
85	Management of Stage D1 Adenocarcinoma of the Prostate: The Johns Hopkins Experience 1974 to 1987. Journal of Urology, 1990, 144, 1425-1432.	0.4	160
86	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2000, 164, 1591-1595.	0.4	160
87	Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12. Nature Genetics, 2008, 40, 1153-1155.	21.4	158
88	INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELS. Journal of Urology, 1998, 160, 449-453.	0.4	157
89	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
90	The Influence of Hormonal Therapy on Survival of Men with Advanced Prostatic Cancer. Journal of Urology, 1982, 128, 335-340.	0.4	150

#	Article	IF	CITATIONS
91	Hormonal Therapy of Prostatic Cancer. Cancer, 1980, 45, 1929-1936.	4.1	148
92	Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology, 1995, 45, 591-596.	1.0	148
93	Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology, 2000, 56, 283-288.	1.0	148
94	Adenocarcinoma of the Prostate Invading the Seminal Vesicle: Definition and Relation of Tumor Volume, Grade and Margins of Resection to Prognosis. Journal of Urology, 1993, 149, 1040-1045.	0.4	145
95	Radical prostatectomy for clinical stage T3a disease. Cancer, 2007, 109, 1273-1278.	4.1	140
96	THE EPIDEMIOLOGY OF PROSTATE CANCER IN JAMAICA. Journal of Urology, 1998, 159, 1984-1987.	0.4	138
97	A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics. American Journal of Human Genetics, 2005, 77, 219-229.	6.2	138
98	Linkage and Association Studies of Prostate Cancer Susceptibility: Evidence for Linkage at 8p22-23. American Journal of Human Genetics, 2001, 69, 341-350.	6.2	137
99	Radical Retropubic Prostatectomy. Urologic Clinics of North America, 1990, 17, 679-684.	1.8	137
100	Physiologic Basis for Hormonal Therapy in Carcinoma of the Prostate. Urologic Clinics of North America, 1975, 2, 125-140.	1.8	135
101	Risk of Cancer in Relatives of Prostate Cancer Probands. Journal of the National Cancer Institute, 1995, 87, 991-996.	6.3	134
102	Radical Prostatectomy for Impalpable Prostate Cancer: The Johns Hopkins Experience With Tumors Found on Transurethral Resection (Stages T1a and T1b) and on Needle Biopsy (Stage T1c). Journal of Urology, 1994, 152, 1721-1729.	0.4	133
103	An Evaluation of the Decreasing Incidence of Positive Surgical Margins in a Large Retropubic Prostatectomy Series. Journal of Urology, 2004, 171, 23-26.	0.4	133
104	Pituitary and gonadal hormones in patients with varicocele. Fertility and Sterility, 1975, 26, 1006-1012.	1.0	132
105	The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary. Journal of Urology, 2012, 188, 2219-2224.	0.4	130
106	Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate, 1995, 27, 25-31.	2.3	128
107	The Influence of Reversible Androgen Deprivation on Serum Prostate-Specific Antigen Levels in Men with Benign Prostatic Hyperplasia. Journal of Urology, 1989, 141, 987-992.	0.4	126
108	Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans. Journal of the National Cancer Institute, 2007, 99, 1525-1533.	6.3	126

#	Article	IF	CITATIONS
109	Radical Prostatectomy, Preservation of Sexual Function, Cancer Control. Urologic Clinics of North America, 1987, 14, 663-673.	1.8	125
110	The role of radical prostatectomy in the management of prostatic cancer. Cancer, 1987, 60, 526-537.	4.1	124
111	Cancer Control following Anatomical Radical Prostatectomy: An Interim Report. Journal of Urology, 1991, 145, 1197-1200.	0.4	124
112	Familial Persistent Müllerian Duct Syndrome. Journal of Urology, 1976, 115, 459-461.	0.4	123
113	Androgen- and Estrogen-Receptor Content in Spontaneous and Experimentally Induced Canine Prostatic Hyperplasia. Journal of Clinical Investigation, 1980, 65, 1051-1059.	8.2	123
114	Original Articles: Prostate Cancer: Pathological Features of Hereditary Prostate Cancer. Journal of Urology, 1995, 153, 987-992.	0.4	122
115	Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. Urology, 2002, 59, 934-938.	1.0	119
116	PROSTATE SPECIFIC ANTIGEN PROGRESSION IN MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY: RESULTS OF LONG-TERM FOLLOWUP. Journal of Urology, 2004, 172, 1860-1864.	0.4	119
117	What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?. Urology, 2010, 76, 710-714.	1.0	119
118	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology, 2003, 62, 86-91.	1.0	117
119	Cavernous Nerve Grafts Restore Erectile Function in Denervated Rats. Journal of Urology, 1991, 145, 380-383.	0.4	114
120	Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology, 2004, 64, 148-151.	1.0	112
121	Estrogen Receptors in Human Prostate: Evidence for Multiple Binding Sites*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 166-176.	3.6	111
122	Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate, 2003, 57, 134-139.	2.3	111
123	Radical Pelvic Surgery with Preservation of Sexual Function. Annals of Surgery, 1988, 208, 391-400.	4.2	107
124	High Anterior Release of the Levator Fascia Improves Sexual Function Following Open Radical Retropubic Prostatectomy. Journal of Urology, 2008, 180, 2557-2564.	0.4	107
125	Genetic Susceptibility of Benign Prostatic Hyperplasia. Journal of Urology, 1994, 152, 115-119.	0.4	106
126	Stage D1 (T1-3, N1-3, M0) Prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology, 1997, 50, 251-255.	1.0	103

#	Article	IF	CITATIONS
127	Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging. Journal of Urology, 2009, 182, 1458-1462.	0.4	102
128	The Management of Rectal Injury During Radical Retropubic Prostatectomy. Journal of Urology, 1992, 147, 905-907.	0.4	100
129	A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENT. Journal of Urology, 2001, 166, 508-516.	0.4	100
130	Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proceedings of the United States of America, 2010, 107, 2136-2140.	7.1	100
131	THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 1998, 159, 1238-1242.	0.4	99
132	Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology, 2003, 61, 791-796.	1.0	98
133	A microassay for the measurement of androgen receptors in human prostatic tissue. Steroids, 1979, 33, 389-406.	1.8	97
134	Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 139-146.	3.6	96
135	Prognostic Factors in Men with Stage D1 Prostate Cancer: Identification of Patients Less Likely to Have Prolonged Survival After Radical Prostatectomy. Journal of Urology, 1994, 152, 1077-1081.	0.4	95
136	Common Sequence Variants of the Macrophage Scavenger Receptor 1 Gene Are Associated with Prostate Cancer Risk. American Journal of Human Genetics, 2003, 72, 208-212.	6.2	94
137	The Significance of Positive Surgical Margin in Areas of Capsular Incision in Otherwise Organ Confined Disease at Radical Prostatectomy. Journal of Urology, 2007, 178, 1306-1310.	0.4	94
138	Evaluation of Linkage and Association of HPC2/ELAC2 in Patients with Familial or Sporadic Prostate Cancer. American Journal of Human Genetics, 2001, 68, 901-911.	6.2	93
139	Individual and cumulative effect of prostate cancer riskâ€associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate, 2009, 69, 1195-1205.	2.3	93
140	Radical Prostatectomy for High Grade Disease: A Reevaluation 1994. Journal of Urology, 1994, 151, 1583-1586.	0.4	92
141	Characterization of the Binding of a Potent Synthetic Androgen, Methyltrienolone, to Human Tissues. Journal of Clinical Investigation, 1978, 61, 150-162.	8.2	91
142	Comparison of Radical Prostatectomy and Iodine 125 Interstitial Radiotherapy for the Treatment of Clinically Localized Prostate Cancer: A 7-Year Biochemical (PSA) Progression Analysis. Urology, 1998, 51, 884-890.	1.0	90
143	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. Journal of Urology, 2013, 190, 1218-1223.	0.4	89
144	A Polymorphism in the <i>CDKN1B</i> Gene Is Associated with Increased Risk of Hereditary Prostate Cancer. Cancer Research, 2004, 64, 1997-1999.	0.9	88

#	Article	IF	CITATIONS
145	Small High Grade Adenocarcinoma of the Prostate in Radical Prostatectomy Specimens Performed for Nonpalpable Disease: Pathogenetic and Clinical Implications. Journal of Urology, 1994, 151, 1587-1592.	0.4	87
146	Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. Urology, 2001, 57, 491-494.	1.0	87
147	The Incidence of Intersexuality in Patients with Hypospadias and Cryptorchidism. Journal of Urology, 1976, 116, 769-770.	0.4	86
148	Linkage of prostate cancer susceptibility loci to chromosome 1. Human Genetics, 2001, 108, 335-345.	3.8	86
149	Nerve Growth Factor, Nerve Grafts and Amniotic Membrane Grafts Restore Erectile Function in Rats. Journal of Urology, 1991, 146, 463-468.	0.4	85
150	Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology, 2001, 57, 1020-1024.	1.0	85
151	Family history of prostate cancer and obesity in relation to highâ€grade disease and extraprostatic extension in young men with prostate cancer. Prostate, 2003, 55, 140-146.	2.3	85
152	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, 160, 97-101.	0.4	84
153	Use of intraoperative video documentation to improve sexual function after radical retropubic prostatectomy. Urology, 2000, 55, 62-67.	1.0	84
154	Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. American Journal of Hematology, 1991, 36, 190-194.	4.1	82
155	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. Journal of Urology, 1999, 162, 1346-1351.	0.4	82
156	Impact of surgical margin status on prostateâ€cancerâ€specific mortality. BJU International, 2012, 110, 1684-1689.	2.5	82
157	Treatment of Benign Prostatic Hyperplasia. New England Journal of Medicine, 1996, 335, 586-587.	27.0	81
158	DEDIFFERENTIATION OF PROSTATE CANCER GRADE WITH TIME IN MEN FOLLOWED EXPECTANTLY FOR STAGE T1C DISEASE. Journal of Urology, 2001, 166, 1688-1691.	0.4	81
159	IMPACT OF SURGICAL DELAY ON LONG-TERM CANCER CONTROL FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 172, 1835-1839.	0.4	81
160	The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate, 1993, 22, 39-42.	2.3	80
161	Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology, 2001, 57, 1112-1116.	1.0	80
162	PREDICTION OF EXTRAPROSTATIC EXTENSION IN THE NEUROVASCULAR BUNDLE BASED ON PROSTATE NEEDLE BIOPSY PATHOLOGY, SERUM PROSTATE SPECIFIC ANTIGEN AND DIGITAL RECTAL EXAMINATION. Journal of Urology, 2005, 173, 450-453.	0.4	80

#	Article	IF	CITATIONS
163	Cigarette Smoking and Prostate Cancer Recurrence After Prostatectomy. Journal of the National Cancer Institute, 2011, 103, 835-838.	6.3	78
164	Radical Retropubic Prostatectomy: The Influence of Accessory Pudendal Arteries on the Recovery of Sexual Function. Journal of Urology, 1995, 154, 150-152.	0.4	77
165	Prognostic Significance of Cleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. European Urology, 2008, 53, 767-776.	1.9	77
166	Retroperitoneal Lymphadenectomy for Testicular Tumors. JAMA - Journal of the American Medical Association, 1971, 217, 309.	7.4	76
167	Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology, 2001, 57, 1033-1037.	1.0	76
168	Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology, 2004, 64, 551-555.	1.0	76
169	Early Androgen Deprivation for Prostate Cancer?. New England Journal of Medicine, 1999, 341, 1837-1838.	27.0	75
170	Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate, 2003, 57, 320-325.	2.3	75
171	Probability of biochemical recurrence by analysis of pathologic stage, gleason score, and margin status for localized prostate cancer. Urology, 2003, 62, 866-871.	1.0	75
172	Weight Gain Is Associated with an Increased Risk of Prostate Cancer Recurrence after Prostatectomy in the PSA Era. Cancer Prevention Research, 2011, 4, 544-551.	1.5	75
173	Systematic detection and repair of subclinical inguinal hernias at radical retropubic prostatectomy. Urology, 2005, 66, 1034-1037.	1.0	74
174	Chemoprevention of Prostate Cancer. New England Journal of Medicine, 2010, 362, 1237-1238.	27.0	74
175	Plasma Androgen Response to hCG Stimulation in Prepubertal Boys with Hypospadias and Cryptorchidism. Journal of Clinical Endocrinology and Metabolism, 1976, 42, 52-59.	3.6	73
176	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	1.0	73
177	Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes. Journal of the National Cancer Institute, 2004, 96, 1240-1247.	6.3	72
178	Standard Versus Age-Specific Prostate Specific Antigen Reference Ranges Among Men With Clinically Localized Prostate Cancer: A Pathological Analysis. Journal of Urology, 1996, 155, 1336-1339.	0.4	71
179	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology, 2001, 58, 746-751.	1.0	71
180	Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Human Genetics, 2002, 110, 122-129.	3.8	71

#	Article	IF	CITATIONS
181	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. Journal of Urology, 2011, 185, 1691-1697.	0.4	70
182	Frozen Section Detection of Lymph Node Metastases in Prostatic Carcinoma: Accuracy in Grossly Uninvolved Pelvic Lymphadenectomy Specimens. Journal of Urology, 1986, 136, 1234-1237.	0.4	69
183	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 160, 660-663.	0.4	69
184	A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology, 2000, 56, 994-999.	1.0	69
185	A Critical Analysis of the Interpretation of Biochemical Failure in Surgically Treated Patients Using the American Society for Therapeutic Radiation and Oncology Criteria. Journal of Urology, 2002, 168, 1419-1422.	0.4	69
186	THE PROSTATIC SPECIFIC ANTIGEN ERA IS ALIVE AND WELL: PROSTATIC SPECIFIC ANTIGEN AND BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 1276-1281.	0.4	67
187	Cause-Specific Actuarial Survival Analysis: A Useful Method for Reporting Survival Data In Men with Clinically Localized Carcinoma of the Prostate. Journal of Urology, 1989, 141, 82-84.	0.4	66
188	Needle Biopsy Associated Tumor Tracking of Adenocarcinoma of the Prostate. Journal of Urology, 1991, 145, 1003-1007.	0.4	65
189	The <scp>M</scp> elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	2.5	64
190	Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology, 1994, 44, 646-650.	1.0	63
191	Surgery and the Reduction of Mortality from Prostate Cancer. New England Journal of Medicine, 2002, 347, 839-840.	27.0	63
192	Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology, 1999, 53, 752-756.	1.0	62
193	Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer, 2004, 100, 1646-1649.	4.1	61
194	Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease. Clinical Cancer Research, 2008, 14, 5819-5824.	7.0	61
195	Blood Transfusion and Anesthetic Practices in Radical Retropubic Prostatectomy. Journal of Urology, 1985, 134, 81-83.	0.4	60
196	Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years. Clinical Cancer Research, 2005, 11, 2883-2888.	7.0	60
197	The Natural History of Men Treated With Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical Prostatectomy. Journal of Urology, 2008, 179, 156-162.	0.4	60
198	What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation. Annals of Internal Medicine, 2012, 157, 137.	3.9	60

#	Article	IF	CITATIONS
199	The Inability of Adrenal Androgens to Stimulate the Adult Human Prostate: An Autopsy Evaluation of Men with Hypogonadotropic Hypogonadism and Panhypopituitarism. Journal of Urology, 1986, 136, 1030-1034.	0.4	58
200	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 2006, 120, 471-485.	3.8	57
201	Prostate Cancer Risk Associated Loci in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2145-2149.	2.5	57
202	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
203	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. Journal of Urology, 2000, 164, 89-92.	0.4	56
204	Polymorphisms in theCYP1A1 gene are associated with prostate cancer risk. International Journal of Cancer, 2003, 106, 375-378.	5.1	56
205	ls It Possible to Compare PSA Recurrence-Free Survival After Surgery and Radiotherapy Using Revised ASTRO Criterion—"Nadir + 2�. Urology, 2008, 72, 389-393.	1.0	56
206	DIGITAL RECTAL EXAMINATION AND IMAGING STUDIES ARE UNNECESSARY IN MEN WITH UNDETECTABLE PROSTATE SPECIFIC ANTIGEN FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1999, 162, 1337-1340.	0.4	55
207	Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. Urology, 2010, 76, 715-721.	1.0	55
208	lleocolic Neobladder Post-Cystectomy: Continence and Potency. Journal of Urology, 1991, 145, 502-504.	0.4	54
209	Association of Cigarette Smoking with Extraprostatic Prostate Cancer in Young Men. Journal of Urology, 2003, 169, 512-516.	0.4	54
210	Prostate cancer kills: Strategy to reduce deaths. Urology, 1994, 44, 463-466.	1.0	53
211	Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Human Genetics, 2001, 108, 430-435.	3.8	53
212	Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?. BJU International, 2010, 105, 1510-1513.	2.5	53
213	Simultaneous Measurement of Progesterone and Androgen Receptors in Human Prostate: A Microassay*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 1089-1099.	3.6	52
214	Peyronie's disease: A newly recognized autosomal-dominant trait. American Journal of Medical Genetics Part A, 1982, 12, 227-235.	2.4	52
215	Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. Cancer, 1990, 65, 1021-1027.	4.1	52
216	Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology, 2002, 59, 85-90.	1.0	52

#	Article	IF	CITATIONS
217	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate, 2013, 73, 1673-1680.	2.3	51
218	Clinical and Endocrinological Evaluation of Patients with Congenital Microphallus. Journal of Urology, 1978, 120, 90-95.	0.4	50
219	A Novel Prostate Cancer Susceptibility Locus at 19q13. Cancer Research, 2009, 69, 2720-2723.	0.9	50
220	Long-term Survival after Hormonal Therapy for Stage D Prostatic Cancer. Journal of Urology, 1979, 122, 185-186.	0.4	49
221	Simultaneous Preperitoneal Hernia Repair During Radical Pelvic Surgery. Journal of Urology, 1987, 137, 1180-1183.	0.4	49
222	No evidence for a role ofBRCA1 orBRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. , 1999, 39, 280-284.		49
223	Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate. Clinical Cancer Research, 2004, 10, 3465-3473.	7.0	49
224	The use of Multiple Variables to Predict Response to Endocrine Therapy in Carcinoma of the Prostate: A Preliminary Report. Journal of Urology, 1984, 131, 694-700.	0.4	48
225	Family history facilitates the early diagnosis of prostate carcinoma. , 1997, 80, 1871-1874.		48
226	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. International Journal of Cancer, 2001, 95, 354-359.	5.1	48
227	Germ-Line Mutation of NKX3.1 Cosegregates with Hereditary Prostate Cancer and Alters the Homeodomain Structure and Function. Cancer Research, 2006, 66, 69-77.	0.9	48
228	Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology, 2000, 55, 372-376.	1.0	47
229	Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. Urology, 2004, 64, 987-990.	1.0	47
230	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate, 2008, 68, 1257-1262.	2.3	47
231	Obesity and Long-Term Survival after Radical Prostatectomy. Journal of Urology, 2014, 192, 1100-1104.	0.4	47
232	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	1.9	47
233	THE SIGNIFICANCE OF PRIOR BENIGN NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER. Journal of Urology, 1999, 162, 1649-1652.	0.4	46
234	Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After Surgery. Journal of Urology, 2011, 185, 1268-1273.	0.4	46

#	Article	lF	CITATIONS
235	Anatomic Extent of Pelvic Lymph NodeÂDissection: Impact on Long-term Cancer-specific Outcomes in Men With Positive Lymph Nodes at Time of Radical Prostatectomy. Urology, 2013, 82, 653-659.	1.0	46
236	Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?. Journal of Urology, 2011, 186, 500-505.	0.4	45
237	The Measurement of Androgen Receptors in Human Prostatic Tissue Utilizing Sucrose Density Centrifugation and a Protamine Precipitation Assay. Journal of Urology, 1977, 117, 309-312.	0.4	44
238	Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. Journal of Urology, 1995, 153, 1015-1019.	0.4	44
239	Tumor Volume Versus Percentage of Specimen Involved by Tumor Correlated with Progression in Stage a Prostatic Cancer. Journal of Urology, 1988, 139, 980-983.	0.4	43
240	Correlation of Prostate Cancer Nuclear Deoxyribonucleic Acid, Size, Shape and Gleason Grade with Pathological Stage at Radical Prostatectomy. Journal of Urology, 1992, 148, 87-91.	0.4	43
241	Familial study of prostate cancer in Jamaica. Urology, 1998, 52, 441-443.	1.0	43
242	Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate, 2005, 64, 356-361.	2.3	43
243	RADICAL RETROPUBIC PROSTATECTOMY. HOW OFTEN DO EXPERIENCED SURGEONS HAVE POSITIVE SURGICAL MARGINS WHEN THERE IS EXTRAPROSTATIC EXTENSION IN THE REGION OF THE NEUROVASCULAR BUNDLE?. Journal of Urology, 2005, 173, 446-449.	0.4	43
244	Extrarenal Manifestations of Renal Cell Carcinoma. Journal of Urology, 1977, 117, 439-440.	0.4	42
245	Sonography in the Diagnosis of Retroperitoneal Fibrosis. Journal of Urology, 1977, 118, 944-946.	0.4	42
246	The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer. Journal of Urology, 1990, 144, 1167-1170.	0.4	41
247	Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate, 2008, 68, 691-697.	2.3	41
248	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	5.4	41
249	Pathological Stage is Higher in Older Men with Clinical Stage B1 Adenocarcinoma of the Prostate. Journal of Urology, 1989, 141, 880-882.	0.4	39
250	Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer, 2003, 98, 2583-2591.	4.1	39
251	Preoperative characteristics of highâ€Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU International, 2012, 110, 1122-1128.	2.5	39
252	Elevation of Serum Gonadotropins Establishes the Diagnosis of Anorchism in Prepubertal Boys with Bilateral Cryptorchidism. Journal of Urology, 1986, 136, 277-279.	0.4	37

#	Article	IF	CITATIONS
253	Long-term autopsy findings following radical prostatectomy. Urology, 1987, 29, 584-588.	1.0	37
254	The use of the preperitoneal approach for the simultaneous repair of inguinal hernia during surgery on the bladder and prostate. World Journal of Surgery, 1989, 13, 555-559.	1.6	37
255	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	37
256	The effect of finasteride in men with benign prostatic hyperplasia. Journal of Urology, 2002, 167, 1102-1107.	0.4	37
257	Critical Appraisal of Management of Rectal Injury During Radical Prostatectomy. Urology, 2010, 76, 1088-1091.	1.0	37
258	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	3.8	37
259	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.8	37
260	Concordance Rates and Modifiable Risk Factors for Lower Urinary Tract Symptoms in Twins. Epidemiology, 2006, 17, 419-427.	2.7	36
261	Chromosome 8q24 risk variants in hereditary and nonâ€hereditary prostate cancer patients. Prostate, 2008, 68, 489-497.	2.3	36
262	Progression after radical prostatectomy for men in their thirties compared to older men. BJU International, 2008, 101, 1503-1506.	2.5	36
263	The Value of Serum Enzymatic Acid Phosphatase in the Staging of Localized Prostate Cancer. Journal of Urology, 1992, 148, 1832-1834.	0.4	35
264	Why Make an Early Diagnosis of Prostate Cancer. Journal of Urology, 1992, 147, 853-854.	0.4	35
265	Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology, 2003, 62, 2-8.	1.0	35
266	Balloon Occlusion of the Internal Spermatic Vein for the Treatment of Varicoceles. JAMA - Journal of the American Medical Association, 1981, 246, 1701.	7.4	34
267	Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia. Journal of Urology, 1997, 157, 876-879.	0.4	34
268	Black Race Does Not Independently Predict Adverse Outcome Following Radical Retropubic Prostatectomy at a Tertiary Referral Center. Journal of Urology, 2006, 176, 515-519.	0.4	34
269	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology, 2006, 67, 115-119.	1.0	34
270	Effect of treatment with 5â€Î± reductase inhibitors on progression in monitored men with favourableâ€risk prostate cancer. BJU International, 2012, 110, 651-657.	2.5	34

#	Article	IF	CITATIONS
271	Improved Hemostasis During Simple Retropubic Prostatectomy. Journal of Urology, 1990, 143, 1203-1204.	0.4	32
272	Endocrine Evaluation of Adults with Mild Hypospadias. Journal of Urology, 1990, 144, 274-277.	0.4	32
273	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
274	Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Human Molecular Genetics, 2007, 16, 1271-1278.	2.9	31
275	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. Journal of Urology, 2001, 165, 864-866.	0.4	30
276	Original Articles. Journal of Urology, 1995, , 987-992.	0.4	30
277	Editorial: The Status of Radical Prostatectomy in the United States in 1993: Where do we go from here?. Journal of Urology, 1994, 152, 1816-1816.	0.4	29
278	Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology, 1999, 53, 175-179.	1.0	29
279	Editorial Comment: Minimally Invasive Treatment of Prostate Cancer. Journal of Endourology, 2001, 15, 447-448.	2.1	29
280	Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology, 2002, 60, 1034-1039.	1.0	29
281	Intensive Intravesical Cheiviotherapy in the Treatment of Flat Carcinoma in Situ: Is it Safe?. Journal of Urology, 1985, 134, 1115-1117.	0.4	28
282	Today men with prostate cancer have larger prostates. Urology, 2000, 56, 839-842.	1.0	28
283	Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology, 2001, 57, 707-711.	1.0	28
284	Pathological Outcomes and Biochemical Progression in Men With T1c Prostate Cancer Undergoing Radical Prostatectomy With Prostate Specific Antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. Journal of Urology, 2006, 176, 554-558.	0.4	28
285	Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology, 1997, 49, 716-720.	1.0	27
286	Adjuvant Radiotherapy After Radical Prostatectomy: Is it Indicated?. Journal of Urology, 1987, 138, 1427-1428.	0.4	26
287	Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?. Urology, 1995, 46, 77-82.	1.0	26
288	Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology, 2003, 61, 781-785.	1.0	26

#	Article	IF	CITATIONS
289	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	1.9	26
290	Re: The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer, by A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh, J. Urol., 150: 110–115, 1993. Journal of Urology, 1994, 152, 172-173.	0.4	25
291	Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology, 1996, 48, 650-653.	1.0	24
292	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World Journal of Urology, 1997, 15, 373-377.	2.2	24
293	BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE. Journal of Urology, 2000, 164, 238-248.	0.4	24
294	Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate, 2003, 56, 37-44.	2.3	24
295	Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Human Genetics, 2014, 133, 347-356.	3.8	24
296	Identification of a prostate cancer susceptibility locus on chromosome 7q11–21 in Jewish families. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1939-1944.	7.1	23
297	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 496-504.	1.9	23
298	Mutational analysis of PINX1 in hereditary prostate cancer. Prostate, 2004, 60, 298-302.	2.3	22
299	Genomeâ€wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses. Prostate, 2010, 70, 735-744.	2.3	22
300	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	1.9	22
301	Radical prostatectomy in men less than 50 years old. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 80-83.	1.6	21
302	The Significance of a Positive Bladder Neck Margin After Radical Prostatectomy: The American Joint Committee on Cancer Pathological Stage T4 Designation is Not Warranted. Journal of Urology, 2010, 183, 151-157.	0.4	21
303	Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCC). Human Genetics, 2012, 131, 1095-1103.	3.8	21
304	Prevalence of the <i><scp>HOXB13</scp></i> â€ <scp>G84E</scp> prostate cancer risk allele in men treated with radical prostatectomy. BJU International, 2014, 113, 830-835.	2.5	21
305	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
306	The Application of Flow Cytometry to the Assessment of Tumor Cell Heterogeneity and the Grading of Human Prostatic Cancer: Preliminary Results. Journal of Urology, 1986, 135, 1194-1198.	0.4	20

#	Article	IF	CITATIONS
307	Sequence variants in the human 25-hydroxyvitamin D3 1-?-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate, 2002, 53, 175-178.	2.3	20
308	GermlineATBF1 mutations and prostate cancer risk. Prostate, 2006, 66, 1082-1085.	2.3	20
309	A genetic variant near <i>GATA3</i> implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate, 2017, 77, 1213-1220.	2.3	19
310	Testicular Descent. Urologic Clinics of North America, 1978, 5, 223-235.	1.8	19
311	Radical Prostatectomy for the Treatment of Localized Prostatic Cancer. , 1988, , 123-140.		19
312	Feedback Regulation of Gonadotropin Secretion in Men. Journal of Urology, 1973, 110, 84-89.	0.4	18
313	Incontinence after radical prostatectomy. Lancet, The, 1999, 353, 2091-2092.	13.7	18
314	Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. Human Genetics, 2003, -1, 1-1.	3.8	17
315	Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003, 528, 45-53.	1.0	17
316	ANALYSIS OF THE PROSTATIC CENTRAL ZONE IN PATIENTS WITH UNILATERAL ABSENCE OF WOLFFIAN DUCT STRUCTURES: FURTHER EVIDENCE OF THE MESODERMAL ORIGIN OF THE PROSTATIC CENTRAL ZONE. Journal of Urology, 1998, 160, 2126-2129.	0.4	16
317	Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. Human Genetics, 2006, 118, 716-724.	3.8	16
318	2008 Whitmore Lecture: Radical prostatectomy—where we were and where we are going. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 246-250.	1.6	16
319	Re: Early Detection of Prostate Cancer: AUA guideline. Journal of Urology, 2013, 190, 1134-1139.	0.4	16
320	RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER PROVIDES DURABLE CANCER CONTROL WITH EXCELLENT QUALITY OF LIFE:. Journal of Urology, 2000, , 1802-1807.	0.4	16
321	FEEDBACK CONTROL OF FSH IN THE MALE: ROLE OF OESTROGEN. European Journal of Endocrinology, 1973, 74, 449-460.	3.7	16
322	Androgen and Estrogen Receptors in the Canine Prostate. Journal of Andrology, 1980, 1, 234-243.	2.0	15
323	This Month in Investigative Urology the Role of Estrogen/Androgen Synergism in the Pathogenesis of Benign Prostatic Hyperplasia. Journal of Urology, 1988, 139, 826-826.	0.4	15
324	Anatomical Studies of the Neurovascular Bundle and Cavernosal Nerves. Journal of Urology, 2005, 174, 566-566.	0.4	15

#	Article	IF	CITATIONS
325	Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy. Journal of Urology, 2007, 178, 1311-1315.	0.4	15
326	Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate, 2012, 72, 410-426.	2.3	14
327	Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?. Journal of Urology, 2016, 195, 330-336.	0.4	14
328	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. BJU International, 2010, 106, 1612-1617.	2.5	13
329	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU International, 2017, 119, 444-448.	2.5	13
330	The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. British Journal of Cancer, 2022, 126, 791-796.	6.4	13
331	The Case for Open Radical Prostatectomy. Urologic Clinics of North America, 2010, 37, 49-55.	1.8	12
332	Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical Prostatectomy. Journal of Urology, 2010, 184, 157-161.	0.4	12
333	Germline mutations in <i>PPFIBP2</i> are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	2.3	12
334	Fine Needle Aspiration of the Prostate—Why has it Taken So Long to Accept?. Journal of Urology, 1986, 135, 334-335.	0.4	11
335	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. International Journal of Cancer, 2016, 138, 2221-2230.	5.1	11
336	Magnetic Resonance Imaging Prior to First Prostate Biopsy–Are we there yet?. European Urology, 2018, 74, 409-410.	1.9	11
337	Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. Prostate, 2021, 81, 703-709.	2.3	11
338	The Phenotypic Expression of Selective Disorders of Male Sexual Differentiation. Journal of Urology, 1978, 119, 627-629.	0.4	10
339	The Search for the Missing Heritability of Prostate Cancer. European Urology, 2017, 72, 657-659.	1.9	8
340	Radical Retropubic and Perineal Prostatectomy. , 2012, , 2801-2829.e4.		8
341	POTENCY AND CONTINENCE FOLLOWING ANATOMIC RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 387.	0.4	8
342	Prostate-specific Antigen and All-Cause Mortality: Results From the Baltimore Longitudinal Study On Aging. Journal of the National Cancer Institute, 2004, 96, 557-558.	6.3	7

#	Article	IF	CITATIONS
343	Re: Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Journal of Urology, 2012, 187, 1267-1268.	0.4	7
344	Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU International, 2013, 111, E306-E309.	2.5	7
345	Prostate Specific Antigen Testing after Radical Prostatectomy—Can We Stop at 20 Years?. Journal of Urology, 2018, 199, 114-119.	0.4	7
346	EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT:. Journal of Urology, 2002, , 1231-1234.	0.4	7
347	Re: Potency-Sparing Radical Retropubic Prostatectomy: A Simplified Anatomical Approach. Journal of Urology, 1996, 155, 294-294.	0.4	6
348	Re: Dutasteride in Localised Prostate Cancer Management: The REDEEM Randomised, Double-Blind, Placebo-Controlled Trial. Journal of Urology, 2012, 188, 110-111.	0.4	6
349	Re: Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Journal of Urology, 2012, 188, 1181-1181.	0.4	6
350	How Charles Huggins made his nobel prize winning discovery—in his own words: An historic audio recording. Prostate, 2012, 72, 1718-1718.	2.3	6
351	Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 529.e1-529.e7.	1.6	6
352	Perfecting nerve-sparing radical prostatectomy: sailing in uncharted waters. Canadian Journal of Urology, 2008, 15, 4230-2.	0.0	6
353	Fine-needle core and aspiration biopsy. A new method for diagnosis of prostatic carcinoma. Cancer, 1990, 63, 1846-1855.	4.1	5
354	Unilateral nerve-sparing radical prostatectomy and hemicystectomy in management of prostate sarcoma]. Urology, 1993, 41, 308-310.	1.0	5
355	RE: HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED CANCER. Journal of Urology, 2001, 166, 2321-2322.	0.4	5
356	ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY: DETAILED DESCRIPTION OF THE SURGICAL TECHNIQUE. Journal of Urology, 2004, 171, 2114-2114.	0.4	5
357	Fine-Mapping and Family-Based Association Analyses of Prostate Cancer Risk Variants at Xp11. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2132-2136.	2.5	5
358	Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Medical Genetics, 2012, 13, 46.	2.1	5
359	INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELS. Journal of Urology, 1998, , 449-453.	0.4	5
360	Randomized study of prostatic cancer. Urology, 1981, 18, 219.	1.0	4

#	Article	IF	CITATIONS
361	RE: RADICAL PROSTATECTOMY: THE VALUE OF PREOPERATIVE, INDIVIDUALLY LABELED APICAL BIOPSIES. Journal of Urology, 2001, 165, 915-915.	0.4	4
362	Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. European Urology, 2016, 69, 191-192.	1.9	4
363	MOLECULAR STAGING OF MEN WITH SEMINAL VESICLE INVASION AND NEGATIVE LYMPH NODES AT RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 235.	0.4	4
364	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER. Journal of Urology, 1998, , 660-663.	0.4	4
365	Re: The Prostate Cancer Prevention Trial: Design, Biases and Interpretation of Study Results. Journal of Urology, 2006, 176, 2744-2744.	0.4	3
366	Urological Oncology: Prostate Cancer. Journal of Urology, 2010, 184, 1982-1985.	0.4	3
367	327: Updated Recurrence-Free Survival (RFS) Prediction Model Following Radical Prostatectomy (RRP). Journal of Urology, 2007, 177, 110-111.	0.4	3
368	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. Journal of Urology, 1999, , 1346-1351.	0.4	3
369	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2000, , 1591-1595.	0.4	3
370	Editorial: Localized Prostate Cancer-Mortality and Morbidity. Journal of Urology, 1997, 157, 1773-1773.	0.4	2
371	Re: Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival. Journal of Urology, 2010, 183, 2466-2467.	0.4	2
372	Re: Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial. Journal of Urology, 2011, 185, 1274-1275.	0.4	2
373	How Surgical Innovation Reduced Death and Suffering From Prostate Cancer. Journal of Craniofacial Surgery, 2013, 24, 49-50.	0.7	2
374	Joseph J. Kaufman: Renaissance Man. Urology, 2015, 85, 487-490.	1.0	2
375	Radical Retropubic Prostatectomy. Journal of Urology, 1995, , 150-152.	0.4	2
376	Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia. Journal of Urology, 1997, , 876-879.	0.4	2
377	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. Journal of Urology, 2001, , 864-866.	0.4	2
378	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer Journal of Clinical Oncology, 2017, 35, 5020-5020.	1.6	2

#	Article	IF	CITATIONS
379	Benign and Malignant Neoplasms of the Prostate. Journal of Urology, 1992, 148, 1352-1356.	0.4	1
380	Re: Quality of Life: Radical Prostatectomy Versus Radiation Therapy for Prostate Cancer. Journal of Urology, 1996, 155, 2038-2038.	0.4	1
381	TROUSSEAU'S SYNDROME IN A PATIENT WITH METASTATIC PROSTATE CANCER. Journal of Urology, 2000, 163, 1877-1877.	0.4	1
382	Urologic Oncology: Prostate Cancer. Journal of Urology, 2003, 170, 1448-1453.	0.4	1
383	Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer. Cancer Letters, 2005, 219, 177-182.	7.2	1
384	Re: Physical Activity and Survival After Prostate Cancer Diagnosis in the Health Professionals Follow-Up Study. Journal of Urology, 2011, 186, 903-903.	0.4	1
385	Re: Perineural Invasion Predicts Increased Recurrence, Metastasis, and Death From Prostate Cancer Following Treatment With Dose-Escalated Radiation Therapy. Journal of Urology, 2012, 187, 911-911.	0.4	1
386	The Gleason Grading System: A Complete Guide for Pathologists and CliniciansEpsteinJ.I.: The Gleason Grading System: A Complete Guide for Pathologists and Clinicians. In: . Philadelphia: Lippincott Williams & Wilkins2013. 224 pages Journal of Urology, 2013, 189, 1173-1173.	0.4	1
387	Re: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. Journal of the National Cancer Institute, 2014, 106, djt432-djt432.	6.3	1
388	Prostate Cancer Screening. New England Journal of Medicine, 2017, 376, 2401-2402.	27.0	1
389	If You Want to Make an Important Discovery, Listen to Your Patients. European Urology, 2017, 72, 482.	1.9	1
390	Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score. Prostate, 2018, 78, 1063-1068.	2.3	1
391	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	1
392	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, , 97-100.	0.4	1
393	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. Journal of Urology, 2000, , 89-92.	0.4	1
394	Radioimmunoassay for Prostatic Acid Phosphatase. Journal of Urology, 1980, 124, 753-754.	0.4	0
395	Re: Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment. Journal of Urology, 1996, 155, 1705-1705.	0.4	0
396	Re: Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer. Journal of Urology, 1997, 157, 965-965.	0.4	0

#	Article	IF	CITATIONS
397	RE: RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2000, 164, 1322-1323.	0.4	0
398	UROLOGICAL ONCOLOGY: PROSTATE CANCER. Journal of Urology, 2001, 166, 1574-1584.	0.4	0
399	Bilateral Nerve Grafting During Radical Retropubic Prostatectomy: Extended Follow-up. Journal of Urology, 2002, 168, 376-377.	0.4	0
400	Preoperative PSA Level Significantly Associated With Interval to Biochemical Progression After Radical Retropubic Prostatectomy. Journal of Urology, 2005, 173, 1580-1580.	0.4	0
401	Laparoscopic Radical Prostatectomy: Is Intact Organ Removal Attainable? Study of Margin Status. Journal of Urology, 2005, 174, 568-568.	0.4	0
402	Obesity and the Risk of Prostate Cancer. Journal of Urology, 2005, 174, 146-146.	0.4	0
403	Re: Knowledge and Use of Finasteride for the Prevention of Prostate Cancer. Journal of Urology, 2011, 185, 514-515.	0.4	0
404	Re: Salvage Radiation in Men After Prostate-Specific Antigen Failure and the Risk of Death. Journal of Urology, 2011, 186, 1876-1876.	0.4	0
405	Re: A Population-Based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. Journal of Urology, 2012, 188, 2227-2228.	0.4	0
406	Re: Lih-Ming Wong, Neil Fleshner, Antonio Finelli. Impact of 5-Alpha Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer: A Time-dependent Covariate Reanalysis. Eur Urol 2013;64:343. European Urology, 2013, 64, e67.	1.9	0
407	Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal of Urology, 2014, 191, 559-561.	0.4	0
408	Reply to Filippo Alongi, Rosario Mazzola, Sergio Fersino's Letter to the Editor re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. Eur Urol 2016:69:191–2. European Urology. 2016. 70. e162.	1.9	0
409	Re: Association of Treatment with 5α-Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer. European Urology, 2019, 76, 704.	1.9	0
410	RE: Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors—A Large Population-Based Prospective Study. Journal of the National Cancer Institute, 2019, 111, 747-747.	6.3	0
411	IL2 The impact of surgical innovation on reducing death and suffering from prostate cancer. Japanese Journal of Urology, 2011, 102, 64.	0.1	0
412	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy Journal of Clinical Oncology, 2014, 32, 5036-5036.	1.6	0
413	Androgen Receptor Assay in Human Prostate Cancer. , 1983, , 371-379.		0
414	2021 Joseph A. Smith, Jr. Mentorship lecture: Discovery. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0